Lamisil (Terbinafine Hydrochloride)

Terbinafine blocks the fungal enzyme squalene epoxidase, which is essential for producing ergosterol, a key component of fungal cell membranes. Inhibiting this step leads to a buildup of squalene and a shortage of ergosterol, destabilizing the membrane and causing fungal cell death.

The dosage of Lamisil is determined by the prescribing healthcare professional based on the specific infection, patient age, and product formulation. Patients should follow the prescriber’s instructions and the product label for application frequency and duration.

Safety data for topical terbinafine during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lamisil.

To order Lamisil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamisil belongs to the allylamine class, which directly inhibits squalene epoxidase, whereas many other topical antifungals (e.g., azoles) target lanosterol 14‑α‑demethylase. Terbinafine often provides rapid symptom relief and has a favorable safety profile, making it a common first‑line option for dermatophyte infections.

Lamisil should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excessive heat, moisture, and direct sunlight to maintain its stability and effectiveness.

Lamisil is applied topically to the affected skin area, usually once or twice daily as directed by the prescriber. The skin should be clean and dry before application, and the medication should be rubbed in gently until fully absorbed.

While rare, serious adverse reactions can include severe allergic responses such as anaphylaxis, extensive contact dermatitis, and, in cases of significant systemic absorption, liver enzyme elevations. Patients should seek medical attention if they experience signs of a serious reaction.

Individuals with a known hypersensitivity to terbinafine or any component of the formulation should avoid using Lamisil. It is also not recommended for children under two years of age unless specifically prescribed, and caution is advised for patients with existing liver disease.